Kritik – Sacubitril/Valsartan
Generelle Probleme: Rasche Zulassung – 2014 Phase-III-Studie, 2015 Zulassung (FDA, EMA), 2016 in US-LL (ACC/AHA/HFSA) und in EU/DE-LL (ESC, NVL) für HI https://clinicaltrials.gov/ct2/show/NCT01035255 https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-entresto https://www.ema.europa.eu/en/medicines/human/EPAR/entresto… Weiterlesen »Kritik – Sacubitril/Valsartan